Blood proteins have the capacity to predict the appearance of more than 60 diverse diseasesaccording to new research published in ‘Nature Medicine‘And carried out as part of an international research association between GSK, the Queen Mary University of London, the University College of London, the University of Cambridge and the Institute of Health of Berlin at the Charité Universitätsmedizin (Germany).
In depth
The researchers used data from the Pharmaceutical Proteomic project of the United Kingdom (UK Biobank Pharma Proteomics Project, UKB-PPP), the largest proteomic study conducted to datewith measurements of approximately 3,000 plasma proteins of a randomly selected set More than 40,000 Biobanco participants in the United Kingdom.
Protein data are linked to the electronic medical records of the participants. The authors used advanced analytical techniques to identify, for each disease, a ‘signature‘between 5 and 20 most important proteins for prediction.
Researchers report on the capacity of ‘firms’ of protein to predict the appearance of 67 diseases, including Multiple myeloma, no Hodgkin lymphom.
Protein prediction models obtained better results than models based on registered clinical information. Prediction based on blood cell counts, cholesterol, renal function and diabetes tests (Glycosylated hemoglobin) had a lower performance than Protein prediction models in most examples.
More details
The benefits that It contributes to patients the measurement and analysis of the risk of suffering a heart attack or a stroke in the future (cardiovascular risk scores) are well established. This research opens new prediction possibilities for a wide range of diseases, including the rarest. Many of them may take months and years to diagnose, and this investigation offers totally new opportunities for timely diagnoses.
These findings They require validation in different populations, including people with and without symptoms and signs of diseases and in different ethnic groups.
“We are Very excited with the opportunity to identify new markers for detection and diagnosis from the thousands of proteins that circulate and can now be measured in human blood. What we need urgently are proteomic studies of different populations to validate our effective findings and evidence that can Measure the relevant proteins for the disease According to clinical standards with affordable methods, “says the main author and director of the Institute for the University Investigation of Precision Health Care (Phuri) of the Queen Mary University of London, Claudia Langenberg.
For her part, the research student at GSK and the University of Cambridge at that time and now postdoctoral researcher in Phuri, the doctor Julia Carrasco Zanini Sánchezpoints out that “several of the protein firms had a similar or even better performance than that of the proteins that had already been tested by their potential as Detection tests, such as the specific prostate antigen for prostate cancer“
To take into account
“Therefore, we are Very excited With the opportunities that our protein firms can have for early detection and, ultimately, to improve the prognosis of many diseases, including serious diseases such as multiple myeloma and idiopathic pulmonary fibrosis. We identify so many promising examples that the next step is Select high priority diseases and evaluate your proteomic prediction in a clinical environment“He adds.
The main co -author, the vice president and director of GSK’s genetics and genomics, Dr. Robert Scott, points out that “a Key challenge in drug development is the identification of patients most likely to benefit from new medications“And that” this work demonstrates how promising the use of large -scale proteomic technologies to identify individuals with high risk in a wide range of diseases, and align with Your approach to use technology to deepen the understanding of biology and human diseases“
#investigation #shows #blood #proteins #predict #risk #developing #diseases
